Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Leases: 2013-2018

Historic Capital Leases for Amphastar Pharmaceuticals (AMPH) over the last 5 years, with Dec 2018 value amounting to $1.1 million.

  • Amphastar Pharmaceuticals' Capital Leases fell 22.25% to $1.1 million in Q4 2018 from the same period last year, while for Dec 2018 it was $1.1 million, marking a year-over-year decrease of 22.25%. This contributed to the annual value of $1.1 million for FY2018, which is 22.25% down from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Capital Leases stood at $1.1 million for Q4 2018, which was down 6.64% from $1.1 million recorded in Q3 2018.
  • Amphastar Pharmaceuticals' Capital Leases' 5-year high stood at $1.9 million during Q2 2016, with a 5-year trough of $802,000 in Q4 2015.
  • Moreover, its 3-year median value for Capital Leases was $1.4 million (2017), whereas its average is $1.4 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Capital Leases surged by 101.25% in 2016 and then fell by 22.25% in 2018.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Capital Leases stood at $1.0 million in 2014, then decreased by 21.53% to $802,000 in 2015, then surged by 101.25% to $1.6 million in 2016, then dropped by 15.92% to $1.4 million in 2017, then declined by 22.25% to $1.1 million in 2018.
  • Its Capital Leases stands at $1.1 million for Q4 2018, versus $1.1 million for Q3 2018 and $1.2 million for Q2 2018.